HomeDTIL • NASDAQ
add
Precision BioSciences Inc
Previous close
$9.11
Day range
$8.93 - $9.29
Year range
$8.25 - $19.43
Market cap
65.54M USD
Avg Volume
47.52K
P/E ratio
44.85
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 49.90M | 152.15% |
Operating expense | 25.75M | 12.37% |
Net income | 32.75M | 375.41% |
Net profit margin | 65.63 | 209.22% |
Earnings per share | 4.67 | 255.67% |
EBITDA | 25.24M | 2,268.21% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 123.57M | -10.32% |
Total assets | 165.80M | -8.75% |
Total liabilities | 91.09M | -38.31% |
Total equity | 74.71M | — |
Shares outstanding | 7.23M | — |
Price to book | 0.87 | — |
Return on assets | 34.44% | — |
Return on capital | 69.47% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | 32.75M | 375.41% |
Cash from operations | -14.87M | 29.64% |
Cash from investing | -28.00K | 97.35% |
Cash from financing | 702.00K | -62.10% |
Net change in cash | -14.20M | 30.20% |
Free cash flow | 21.17M | 321.98% |
About
Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform. Wikipedia
Founded
2006
Website
Employees
110
